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Abstract 
Background: Fever of unknown origin (FUO) is a perplexing medical problem. The 
causes for FUO are more than 200 diseases. The aim of the study was to present human 
clinical cases of Coxiella burnetii infection debuting as FUO. 
Methods: The following methods were conducted in the study: literature search, 
laboratory, imaging, and statistical methods. Criteria of Durack and Street were applied for 
FUO definition. For the etiological diagnosis indirect immunoenzyme assay (ELISA) for 
antibodies detection against Coxiella burnetii was used (cut-off = 0.481–0.519). 
Results: From 2008 until 2015, nine patients with FUO caused by C. burnetii were 
hospitalized at the Military Medical Academy of Sofia. Male gender was predominant 
(male/female – 77.8% /22.2%), mean age was 48.78±14.52 years (range: 26–67), hospital 
stay was 9.78±2.95 days (range: 5–15), fever duration was 54.33±56.23 days (range: 21–
180). Laboratory investigations estimated the elevation of erythrocyte sedimentation rate 
49.11±31.74mm/h (95%CI = 13.09–111.31), C-reactive protein 37.68±37.62mg/L (95% 
CI = 36.07–111.42) and fibrinogen 5.69±1.59g/L (95% CI=2.57–8.81). The mean values 
of liver enzymes were in reference range. Among imaging tests, abdominal ultrasound and 
X-ray demonstrated 33.3% contribution to the final diagnosis. Transthoracic 
echocardiography found 22.2% contribution. Serological methods presented 100% 
contribution. 
Conclusion: C. burnetii infection was accepted as a final diagnosis among 9 patients with 
FUO based on the integrated information from the applied methods. Active search and 
establishment of this pathogen among FUO should lead to avoiding potential 
complications and consequences in case of untreated patients infected with C. burnetii. 
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For the first time, fever of unknown origin (FUO) was defined in 1961 by Robert G. 
Petersdorf and Paul B. Beeson (1). They gave the following definition of FUO: (a) fever 
higher than 38.3
0С (1010F) in several measurements; (b) duration of fever for at least 3 
weeks; (c) diagnosis remains unclear after a week of active diagnosis in a hospital (1). In 
1991 two other American researchers David T. Durack and Alan C. Street changed the 
third criterion for FUO in the following form: „the diagnosis remains unspecified after 3 
outpatient visits or 3 days in hospital” (2). Dutch scientist Chantal P. Bleeker-Rovers has 
presented a new definition of FUO in 2007 (3). Professor Bleeker-Rovers retained the first 
two criteria and removed the third criterion (3, 4). The researcher added a new third 
criterion – exclusion of immunocompromised individuals and a fourth criterion for a 
mandatory diagnostic investigation (3, 4).  
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Reasons for FUO are arranged in five groups: (a) 
infectious diseases, (b) neoplasms, (c) non-infectious 
inflammatory diseases, (d) miscellaneous and (e) 
undiagnosed (5, 6). Until 2012 in Bulgaria, there was little 
scientific work and few articles on FUO (7-11). Since 2012, 
researchers from Department of Infectious Diseases, Military 
Medical Academy, Sofia (Bulgaria) have been starting 
comprehensive projects in FUO (12, 13). They did 
retrospective and prospective FUO studies for Bulgaria (14-
21). For the period 2008 to 2015 in Bulgaria, the registered 
cases of human Q-fever were 158 (0.27 cases per 100 
thousand population; 95% CI = 16.08–23.41) (22). The 
highest morbidity of human Q-fever was observed in Plovdiv 
district (23). The aim of the study is to present a case series 
of Coxiella burnetii infection presenting as FUO in a 
Bulgarian hospital.  
 
 
Methods  
Study design and participants: An observational study was 
conducted between January 2008 and March 2015 at the 
Department of Infectious Diseases, Military Medical 
Academy, Sofia (Bulgaria). The definition of Durack and 
Street for FUO was applied in the present study (2). Patients 
older than 18 years were enrolled (2). Measurements of body 
temperature were performed with a digital thermometer MC-
343F-E (OMRON Flex Temp Smart; OMRON Healthcare 
Co., Ltd., Ukyo-ku, Kyoto, Japan), accuracy of measurement 
±0.1
0С (range: 32.00С–42.00С). The thermometry was 
realized in the axillary area under the supervision and control 
of a physician or nurse at an ambient temperature of 20.0
0
C 
to 28.0
0
C.  
Laboratory and diagnostic tests: Various laboratory tests 
have been applied during the diagnostic process: WBC, ESR, 
Fibrinogen, CRP, AST, ALT, GGT, AP and other laboratory 
indicators. Depending on the medical history and physical 
examination and diver imaging studies were carried out: 
abdominal ultrasound, x-ray, transthoracic 
echocardiography, computed tomography. Etiological 
diagnosis included culture methods, serology tests and 
molecular assays. Coxiella burnetii phase 1 IgA/IgG and 
Coxiella burnetii phase 2 IgG/IgM antibodies were detected 
in serum by indirect immunoenzyme assay (SERION ELISA 
classic, Virion/Serion, Würzburg, Germany), and according 
to the manufacturer’s instructions. Coxiella burnetii phase 1 
IgA/IgG sensitivity 94.2%, specificity 96.2%; C. burnetii 
phase 2 IgG sensitivity 93.4%, specificity 98.5%; and C. 
burnetii phase 2 IgM sensitivity 94.4%, specificity >99%. 
The cutoff-evaluation of C. burnetii phase 1 IgA and IgG, 
respectively C. burnetii phase 2 IgM were calculated for 
each sample according to the manufacturer’s prescription 
and varying between from 0.481 to 0.519. Coxiella burnetii 
phase 1 IgA/IgG, resp. C. burnetii phase 2 IgM were defined 
as positive when optical density (OD) sample is more than 
10% over OD cutoff, as negative when OD sample is more 
than 10% under OD cutoff, and as borderline when OD 
sample +/– 10% of OD cut-off. SERION ELISA classic C. 
burnetii phase 2 IgG was expressed in U/ml titer using a 
mathematical calculation and was defined as positive when 
the titer was >30 U/ml, as negative when the titer was <20 
U/ml, and as borderline when the titer was 20–30 U/ml.  
Statistics: Statistical analysis was performed by Excel 2007 
(Microsoft, Redmond, Washington, USA) and SPSS 
Statistics 19.0 (IBM Corp., Armonk, New York, USA). 
When p-value <0.05 the result was statistically significant.  
Ethics: The medical procedures of this study were approved 
by the Local Ethics Committee of Military Medical 
Academy, Sofia, Bulgaria (3 St. Georgi Sofiyski Str., 1606 
Sofia).  
 
 
Results  
In the period of January 2008 to March 2015, one 
hundred and thirteen patients with FUO were investigated at 
the Department of Infectious Diseases, Military Medical 
Academy, Sofia (Bulgaria). The distribution of etiological 
groups was: 58.4% infections, 4.4% neoplasms, 13.3% non-
infectious inflammatory diseases, 5.3% miscellaneous and 
18.6% undiagnosed cases.  
After a comprehensive diagnostic process nine patients 
were classified as C. burnetii infection. They had serological 
data for Q-fever. The final diagnosis was determined by 
medical history, laboratory data and positive serological 
results.  
We analyzed the epidemiological, clinical and laboratory 
parameters in the group of cases with diagnosed Q-fever. 
Male gender was predominant (male/female – 
77.8%/22.2%), mean age was 48.78±14.52 years (range: 26–
67), hospital stay was 9.78±2.95 days (range: 5–15), fever 
duration was 54.33±56.23 days (range: 21–180). Clinical 
data of patients with C. burnetii infection were presented in 
table 1. Laboratory investigations estimated the elevation of 
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ESR 49.11±31.74mm/h (95% CI=13.09–111.31), CRP 
37.68±37.62mg/L (95% CI=36.07–111.42) and fibrinogen 
5.69±1.59g/L (95% CI=2.57–8.81). Laboratory parameters 
were shown in table 2. The mean values of liver enzymes 
were in reference range. The serological results for C. 
burnetii infection were presented in table 3. The abdominal 
ultrasound and x-ray demonstrated 33.3% contribution to the 
final diagnosis. Transthoracic echocardiography found 
22.2% contribution. Serological methods presented 100% 
contribution.  
 
Table 1. Clinical data of patients with Coxiella burnetii infection presenting as FUO 
Patient Sex/Age Sweats Chills Fatigue Cough Arthralgias Animal contact Fever, duration (days) 
1 M
*
/60 No Yes No No No No 180 
2 M/50 No No Yes Yes No No 21 
3 M/67 Yes Yes Yes No No No 30 
4 F
**
/26 No Yes Yes Yes Yes Yes 21 
5 F/53 No No Yes No No No 119 
6 M/33 No Yes Yes No Yes No 30 
7 M/57 No No Yes No Yes No 30 
8 M/60 Yes Yes No Yes Yes No 30 
9 M/33 Yes Yes No Yes No Yes 30 
             *M: Male    **F: Female      
Table 2. Laboratory data of nine patients with Q-fever presenting as FUO 
Patient WBC 
(3.5-10.5 
x10
9
/L) 
ESR 
(≤ 20 
mm/h) 
Fibrinogen 
(2.0-4.5 
g/L) 
CRP 
(0.0-5.0 
mg/L) 
AST 
(5-40 
IU/L) 
ALT 
(5-40 
IU/L) 
GGT 
(10-50 
IU/L) 
AP 
(64-300 
IU/L) 
1 7 39 7 ND 18 16 21 161 
2 7 36 8 64 15 15 46 ND 
3 3 95 5 17 110 58 135 418 
4 7 5 3 2 39 13 22 121 
5 8 87 6 42 14 27 28 270 
6 13 82 ND 107 38 65 47 330 
7 9.3 30 5.1 7.7 13 16 38 120 
8 7 48 5.7 60 19 28 25 213 
9 6 20 ND 1.7 41 96 25 ND 
WBC: white blood cells; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; AST: aspartate transaminase; ALT: alanine transaminase; 
GGT: gamma-glutamyl transferase; AP: alkaline phosphatase; ND: no data available 
 
Table 3. Serological results of Coxiella burnetii in Bulgarian patients with FUO 
Patient Phase 1 IgA Phase 1 IgG Phase 2 IgG Phase 2 IgM 
Cut-off Result Cutoff Result Cutoff * Result (U/ml) Cutoff Result 
1 0.497 0.500 0.512 0.515 NA 67 0.486 0.632 
2 0.502 0.509 0.491 0.498 NA 123 0.507 0.712 
3 0.485 0.481 0.499 0.495 NA 97 0.489 0.698 
4 0.493 0.485 0.514 0.506 NA 79 0.481 0.654 
5 0.498 0.503 0.482 0.487 NA 169 0.512 0.747 
6 0.511 0.519 0.493 0.501 NA 189 0.517 0.769 
7 0.484 0.481 0.515 0.512 NA 85 0.486 0.683 
8 0.519 0.512 0.491 0.484 NA 158 0.501 0.734 
9 0.507 0.502 0.483 0.478 NA 173 0.519 0.758 
                              * Positive: >30 U/ml; Negative:  <20 U/ml; Borderline: 20–30 U/ml; NA: not applicable 
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Discussion  
Infections are the most common causes of FUO. The 
leading infectious diseases are tuberculosis, infective 
endocarditis and abscess (24, 25). Q-fever is a rare cause of 
FUO. Xiao-chun Shi et al. reported 0.1% cases of C. burnetii 
infection presenting as FUO in a study based on total 997 
FUO patients (26).  
Researchers from Greece announced 2.9% cases of Q-
fever in group of infectious diseases [n (ID)=34] among one 
hundred and twelve patients with FUO (27). Mete et al. 
found 1.0% cases of C. burnetii debuting as FUO in 
population of 100 cases (28). Investigators from United 
Kingdom presented 4.3% cases of Q-fever among twenty 
three patients with FUO (29).  
Ko et al announced seven cases of acute infection with C. 
burnetii in Taiwan (30). Ben-Baruch et al from Israel found 
9.1% cases of Q-fever in the group of diagnosed infectious 
diseases among FUO population with 75 participants [n(ID) 
= 11; n(FUO) = 75] (31). French investigator Thierry Zenone 
presented 3.7% cases of C. burnetii infection in the group of 
diagnosed patients [n(Diag) = 107; n(Undiag) = 144] (32). In 
the present study, we reported nine cases (9/113; 7.96%) of 
Q-fever presenting as FUO. In comparison with other 
studies, the announced cases of C. burnetii infection are 
high.  
Divers reasons could influence this result. First, the 
geographic location of Bulgaria and local climate create a 
good condition for the development of this infection. 
Second, the hygiene requirements of livestock farms (cows, 
sheep, goats) are very often lowered. Third, veterinary 
control of dairy products (milk, cheese, yellow cheese, 
butter) is not always enough protective in the rural area of 
Bulgaria. Fourth, weather conditions for the development of 
ticks (as vectors for transmission of C. burnetii) are 
appropriate in our country.  
In the present study, the mechanism of infection is 
unclear, the epidemiological data are not enough to 
summarize the potential way of transmission. All this require 
further researches in the field of Q-fever and FUO in Bulgaria. 
In conclusion, the diagnostic detection of any case of FUO is a 
serious challenge for the physician. Q-fever as a cause of 
FUO is a reason, requiring a high attention in the diagnostic 
process.  
The scientific data for the connection between Q-fever 
and FUO are small. All these facts are a start point for 
further investigations.  
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